Top

BMC Pregnancy and Childbirth

Published in:

Open Access 01-12-2021 | Preterm Labor | Research

The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation

Authors: Yas Arimi, Narges Zamani, Mamak Shariat, Hossein Dalili

Published in: BMC Pregnancy and Childbirth | Issue 1/2021

Abstract

Background

Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation.

Methods

This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome.

Results

The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008, RR = 1.59 95% CI (1.12–2.27)) and requiring more respiratory support (71% versus 50%, p = 0.002, RR = 1.43 95% CI (1.13–1.80)) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death.

Conclusion

the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.

Available only for authorised users

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016;128(4):e155–64. https://doi.org/10.1097/AOG.0000000000001711.CrossRef

Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454. https://doi.org/10.1002/14651858.CD004454.pub3.CrossRefPubMed

Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515–25.PubMed

Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 1: outcomes. Nat Rev Endocrinol. 2014;10(7):391–402. https://doi.org/10.1038/nrendo.2014.73 Epub 27 May 2014.CrossRefPubMed

Briceño-Pérez C, Reyna-Villasmil E, Vigil-De-Gracia P. Antenatal corticosteroid therapy: historical and scientific basis to improve preterm birth management. Eur J Obstet Gynecol Reprod Biol. 2019;234:32–7. https://doi.org/10.1016/j.ejogrb.2018.12.025 Epub 6 Jan 2019.CrossRefPubMed

Hrabalkova L, Takahashi T, Kemp MW, Stock SJ. Antenatal corticosteroids for fetal lung maturity - too much of a good thing? Curr Pharm Des. 2019;25(5):593–600. https://doi.org/10.2174/1381612825666190326143814.CrossRefPubMed

Agnew EJ, Ivy JR, Stock SJ, Chapman KE. Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation. J Mol Endocrinol. 2018;61(1):R61–73. https://doi.org/10.1530/JME-18-0077 Epub 2 May 2018.CrossRefPubMedPubMedCentral

Kemp MW, Schmidt AF, Jobe AH. Optimizing antenatal corticosteroid therapy. Semin Fetal Neonatal Med. 2019;24(3):176–81. https://doi.org/10.1016/j.siny.2019.05.003 Epub 8 May 2019.CrossRefPubMed

Shanks AL, Grasch JL, Quinney SK, Haas DM. Controversies in antenatal corticosteroids. Semin Fetal Neonatal Med. 2019;24(3):182–8. https://doi.org/10.1016/j.siny.2019.05.002 Epub 29 May 2019.CrossRefPubMed

10.

Morsi A, DeFranco D, Witchel SF. The hypothalamic-pituitary-adrenal Axis and the fetus. Horm Res Paediatr. 2018;89(5):380–7. https://doi.org/10.1159/000488106 Epub 6 Jun 2018.CrossRefPubMed

11.

Wynne K, Rowe C, Delbridge M, Watkins B, Brown K, Addley J, et al. Antenatal corticosteroid administration for foetal lung maturation. F1000Res. 2020;9:219. https://doi.org/10.12688/f1000research.20550.1 eCollection 2020.CrossRef

12.

Battarbee AN. Use of antenatal corticosteroids in preterm Prelabor rupture of membranes. Obstet Gynecol Clin N Am. 2020;47(4):587–94. https://doi.org/10.1016/j.ogc.2020.08.004 Epub 7 Oct 2020.CrossRef

13.

Henry A, Shand A, Welsh A. The short term fetal cardiovascular effects of corticosteroids used in obstetrics. Australas J Ultrasound Med. 2013;16(3):135–41. https://doi.org/10.1002/j.2205-0140.2013.tb00101.x Epub 31 Dec 2015.CrossRefPubMedPubMedCentral

14.

Kamath-Rayne BD, Rozance PJ, Goldenberg RL, Jobe AH. Antenatal corticosteroids beyond 34 weeks gestation: what do we do now? Am J Obstet Gynecol. 2016;215(4):423–30. https://doi.org/10.1016/j.ajog.2016.06.023 Epub 21 Jun 2016.CrossRefPubMed

15.

Groom KM. Antenatal corticosteroids after 34 weeks' gestation: do we have the evidence? Semin Fetal Neonatal Med. 2019;24(3):189–96. https://doi.org/10.1016/j.siny.2019.03.001 Epub 2019 Apr 2.CrossRefPubMed

16.

ACOG technical bulletin. Preterm labor. Number 206--June 1995 (Replaces No. 133, October 1989). Int J Gynaecol Obstet. 1995;50(3):303–13.CrossRef

17.

Gyamfi-Bannerman C, Gilbert S, Landon MB, Spong CY, Rouse DJ, Varner MW, et al. Effect of antenatal corticosteroids on respiratory morbidity in singletons after late-preterm birth. Obstet Gynecol. 2012;119(3):555–9.CrossRef

18.

Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016;374(14):1311–20.CrossRef

19.

Ontela V, Dorairajan G, Bhat VB, Chinnakali P. Effect of antenatal steroids on respiratory morbidity of late preterm newborns: a randomized controlled trial. J Trop Pediatr. 2018;64(6):531–8.CrossRef

20.

Shaikh N, Faizi S, Rai L. Respiratory morbidity in late-preterm births: a prospective observational study at a tertiary care hospital. J Obstet Gynaecol India. 2016;66(Suppl 1):301–6.CrossRef

21.

Groom KM. Antenatal corticosteroids after 34weeks' gestation: do we have the evidence? Semin Fetal Neonatal Med. 2019;24(3):189–96.CrossRef

Title: The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
Authors: Yas Arimi
Narges Zamani
Mamak Shariat
Hossein Dalili
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Preterm Labor
Published in: BMC Pregnancy and Childbirth / Issue 1/2021
Electronic ISSN: 1471-2393
DOI: https://doi.org/10.1186/s12884-021-04246-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Socio-demographic characteristics and outcomes of pregnant women who delivered prior to and after the termination of the one-child policy in China: a comparative study

Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19)

Sexual function in Chinese women from pregnancy to postpartum: a multicenter longitudinal prospective study

Is a ‘guideline-compliant’ primary cesarean delivery associated with a modified risk for maternal and neonatal morbidity?: a clinical evaluation of the 2014 ACOG/SMFM obstetric care consensus statement

Prevalence and clinical, social, and health care predictors of miscarriage

Determinants of antenatal care and skilled birth attendance services utilization among childbearing women in Guinea: evidence from the 2018 Guinea Demographic and Health Survey data